e-Drug3D
1855
MAYTANSINE
INN
MAYTANSINE
ADO-TRASTUZUMAB EMTANSINE
cas 139504-50-0
CLASS
ANTINEOPLASTIC
TREATMENT OF PATIENTS WITH HER2-POSITIVE, METASTATIC BREAST CANCER WHO PREVIOUSLY RECEIVED TRASTUZUMAB AND A TAXANE, SEPARATELY OR IN COMBINATION
HER2-TARGETED ANTIBODY-DRUG CONJUGATE (ADC)
EMTANSINE REFERS TO THE MCC-DM1
DM1 IS A MAYTANSINE DERIVATIVE AND MCC IS STABLE THIOETHER LINKER (4-[N-MALEIMIDOMETHYL] CYCLOHEXANE-1-CARBOXYLATE)
LEAD TO THE RELEASE OF DM1 A MICROTUBULE INHIBITOR
ROUTE (list)
INJECTION
ATC code
L01FD03
PK parameters
PPB 93 PERCENT
TARGET TUBULIN
Receptor tyrosine-protein kinase erbB-2 UNIPROT P04626 ERBB2_HUMAN
Tubulin beta UNIPROT P07437 TBB5_HUMAN
Formula:
C35H48ClN3O10S
Calculated chemical properties:
MW 738.28
NB_atoms 50
XLogP 3.83
PSA 146.757
NB_HD 2
NB_HA 13
fsp3 0.60
Lipinski(0=no;1=yes) 0
NB_atoms 50
XLogP 3.83
PSA 146.757
NB_HD 2
NB_HA 13
fsp3 0.60
Lipinski(0=no;1=yes) 0